rheumatoid
arthriti
ra
chronic
inflammatori
system
autoimmun
diseas
affect
worldwid
popul
roughli
gener
popul
western
countri
ra
two
three
time
common
women
men
ra
manifest
chronic
synov
progress
destruct
joint
leukocyt
infiltr
cartilag
destruct
bone
eros
approxim
half
afflict
patient
becom
disabl
progress
diseas
ra
mediat
predominantli
cell
overexpress
proinflammatori
cytokin
particularli
joint
order
test
efficaci
potenti
ra
therapeut
understand
mechan
diseas
collageninduc
arthriti
cia
model
often
use
cia
typic
induc
immun
rodent
bovin
chick
type
ii
collagen
togeth
adjuv
combin
lead
immun
attack
host
nativ
collagen
involv
compon
innat
adapt
immun
system
emphasi
regul
proinflammatori
cytokin
particularli
key
minim
diseas
sinc
detect
joint
ra
patient
mous
cia
share
sever
clinic
histopatholog
immunolog
featur
human
ra
clinic
featur
includ
erythema
edema
synov
pannu
format
cellmedi
inflamm
extens
cartilag
bone
damag
result
joint
deform
similar
commonli
exploit
use
cia
model
ra
tool
investig
novel
approach
prevent
treat
ra
current
treatment
focu
neutral
action
via
mab
receptor
antagonist
howev
intervent
problemat
make
patient
suscept
opportunist
infect
henc
altern
restor
toler
need
sought
view
reduc
autoimmun
use
probiot
restor
immun
homeostasi
reduc
autoimmun
histor
lactic
acid
bacteria
lab
repres
core
probioticbas
intervent
although
recent
nonpathogen
e
coli
attenu
salmonella
bifidobacterium
spp
yeast
like
saccharomyc
boulardii
also
prove
valuabl
tool
novel
therapeut
prophylact
intervent
tradit
molecular
genet
coupl
synthet
biolog
provid
ampl
select
promot
termin
result
dynam
express
level
protein
synthesi
induc
vitro
nisin
control
express
nice
use
promot
silent
vitro
cultur
activ
vivo
subsequ
infect
host
lab
consid
ideal
vector
oral
mucos
deliveri
sinc
inher
nonpathogen
surviv
harsh
condit
gastric
environ
lab
amen
recombin
express
passeng
antigen
ag
stimul
immun
number
pathogen
curb
effect
inflammatori
bowel
diseas
control
prolifer
cancer
cell
use
enzym
replac
therapi
among
applic
current
microbiotabas
therapi
fdaapprov
commerci
avail
fecal
microbiota
transplant
fmt
treat
clostridium
difficil
infect
howev
close
microbiomebas
therapeut
diagnost
current
develop
deliveri
oral
therapeut
repres
signific
advantag
adapt
lab
context
develop
recombin
lactococcu
lacti
oral
deliveri
treat
autoimmun
diseas
similar
fashion
studi
describ
focu
express
immunosuppress
cytokin
oral
administr
probioticbas
therapeut
consid
ideal
gastrointestin
gi
tract
home
cell
stimul
becom
treg
seed
mucos
system
immun
compart
anoth
advantag
use
geneticallymodifi
gm
probiot
shown
effect
safe
previou
work
shown
engin
deriv
industri
dairi
strain
ferment
commerci
milk
yogurtlik
product
appli
treatment
cia
maintain
therapeut
properti
grown
synthet
medium
belong
cytokin
famili
rev
heterodimer
cytokin
compos
contrast
member
famili
potent
antiinflammatori
attribut
properti
mediat
via
bind
chain
result
specif
trigger
cell
b
cell
immunosuppress
number
autoimmun
diseas
model
includ
cia
experiment
autoimmun
encephalomyel
uveiti
type
diabet
inflammatori
bowel
diseas
ibd
psoriasi
previous
shown
express
treg
particularli
express
treg
shown
involv
suppress
autoimmun
diseas
treg
found
commonli
associ
human
treg
also
found
induc
mice
subject
cia
given
potenc
treat
variou
autoimmun
diseas
queri
effect
live
vector
deliveri
accomplish
object
murin
express
l
lacti
subsp
lacti
test
abil
amelior
cia
result
show
highli
effect
treat
cia
via
stimul
treg
produc
suppress
proinflammatori
cytokin
lactococcu
lacti
subsp
lacti
grown
plu
glucos
microbiolog
work
perform
accord
nih
guidelin
initi
attempt
express
control
constitut
promot
yield
rearrang
nonfunct
clone
confirm
notion
difficult
express
stabil
wide
panel
host
unpublish
observ
express
synthet
gene
codonoptim
design
inhous
synthes
genscript
piscathawa
nj
fragment
contain
optim
shinedalgarno
sequenc
properli
space
atg
start
codon
secret
signal
code
region
short
flexibl
linker
code
region
agei
smai
site
end
fragment
excis
agei
gelpurifi
clone
kind
gift
dr
da
mill
univers
california
davi
yield
construct
name
express
achiev
control
nisininduc
promot
born
vector
anim
experi
describ
present
studi
conduct
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
anim
studi
conduct
protocol
approv
montana
state
univers
univers
florida
institut
anim
care
use
committe
male
age
charl
river
laboratori
horsham
pa
usa
maintain
montana
state
univers
anim
resourc
center
univers
florida
anim
center
servic
group
male
induc
cia
use
chicken
collagen
ii
cii
chondrex
redmond
wa
usa
emulsifi
complet
freund
adjuv
cfa
administ
sc
previous
describ
treat
cia
mice
first
oral
gavag
steril
satur
sodium
bicarbon
solut
neutral
stomach
acid
follow
cfu
vector
vehicl
steril
pb
two
dose
regimen
test
three
dose
administ
day
two
dose
given
day
postcii
challeng
clinic
score
measur
doubleblind
fashion
treatment
mice
monitor
day
four
limb
evalu
use
scale
clinic
sign
mild
red
paw
swell
singl
digit
signific
swell
ankl
wrist
erythema
sever
swell
erythema
multipl
joint
maximum
score
per
mous
cell
cellsort
neg
select
magnet
bead
invitrogen
grand
island
ny
usa
axillari
poplit
inguin
lymph
node
ln
yield
puriti
purifi
cell
restimul
platebound
mab
ebiosci
san
diego
ca
usa
plu
solubl
mab
ebiosci
h
similar
previous
describ
cultur
supernat
collect
cytokinespecif
elisa
splenic
ln
cell
stain
fluorochromelabel
mab
ebiosci
san
diego
ca
usa
r
system
minneapoli
mn
usa
fluorochromeconjug
streptavidin
bd
pharmingen
san
jose
ca
usa
flow
cytometri
treg
whole
splenic
ln
cell
cultur
restimul
overnight
cii
tcell
prolifer
chondrex
next
day
cell
stimul
ngml
pma
ionomycin
addit
h
cell
harvest
wash
stain
analyz
previous
describ
measur
inflammatori
cell
arthrit
joint
isol
limb
joint
digest
mgml
collagenas
clostridium
histolyticum
type
iv
sigmaaldrich
st
loui
mo
min
cell
suspens
pass
cell
strainer
similar
previous
describ
leukocyt
stain
analyz
forward
sidescatt
plot
neutrophil
mannwhitney
utest
appli
statist
analyz
clinic
score
differ
arthriti
incid
experiment
group
check
fisher
exact
probabl
test
oneway
anova
perform
analyz
elisa
flow
cytometri
result
data
consid
statist
signific
pvalu
ra
chronic
system
autoimmun
disord
affect
million
patient
us
treatment
progress
degen
diseas
demand
constant
use
antiinflammatori
drug
often
immunosuppress
treatment
increas
suscept
infect
neoplasia
instead
intervent
strategi
focu
redirect
reeduc
cell
respons
produc
toler
instead
inflamm
potenti
superior
treatment
ra
address
void
toler
induct
queri
whether
probiot
lab
engin
express
potent
antiinflammatori
cytokin
figur
would
diminish
arthriti
express
detect
western
blot
analysi
use
rabbit
polyclon
serum
fusion
protein
produc
inhous
test
therapeut
properti
mice
challeng
day
cii
induc
cia
given
similar
cia
often
exploit
investig
tool
test
novel
strategi
therapeut
prevent
treat
ra
mice
randomli
divid
three
group
oral
treatment
vector
steril
pb
two
treatment
paradigm
test
begin
intervent
day
resembl
salmonellacfai
treatment
two
addit
dose
day
figur
begin
intervent
diseas
onset
day
follow
second
dose
day
figur
clinic
score
perform
doubl
blind
follow
day
postinduct
gener
see
chang
diseas
sever
beyond
day
postcii
challeng
use
threedos
regimen
mice
show
symptom
remain
develop
minor
symptom
oppos
pb
vectortr
mice
develop
sever
arthriti
day
postcii
challeng
notabl
sever
diseas
symptom
significantli
less
p
mice
exhibit
averag
clinic
score
contrast
pb
vectortr
mice
eventu
achiev
clinic
score
figur
test
effect
arrest
diseas
diseas
onset
addit
group
cia
mice
treat
use
twodos
regimen
day
treatment
mice
develop
cia
vs
treat
pb
vector
figur
compar
threedos
regimen
diseas
sever
greater
cia
mice
subject
twodos
regimen
although
significantli
less
p
compar
similarli
treat
pb
vectordos
mice
data
show
effect
reduc
symptom
arthriti
incid
diseas
via
immunosuppress
capac
moreov
result
show
fewer
dose
deliv
need
curtail
arthriti
compar
treatment
solubl
protein
analysi
knee
joint
perform
determin
extent
neutrophil
infiltr
agreement
clinic
find
mice
markedli
reduc
cell
neutrophil
infiltr
joint
figur
repres
reduct
compar
pbsdose
vectortr
group
respect
figur
henc
reduc
inflamm
joint
ciachalleng
mice
investig
possibl
mechan
protect
confer
cell
purifi
drain
ln
analyz
cytokin
product
cell
obtain
mice
dose
three
time
pb
vector
describ
figur
level
remain
elev
pbsdose
vectortr
mice
contrast
mice
show
reduct
p
figur
concomitantli
level
significantli
less
p
vector
group
respect
rel
pbsdose
mice
figur
moreov
treatment
significantli
reduc
compar
vectortr
mice
p
minim
stimul
detect
restimul
cell
pbsdose
mice
figur
contrast
cell
vector
group
show
significantli
increas
product
p
respect
differ
vector
group
signific
p
figur
well
stimul
vector
report
other
howev
induc
vectortr
group
insuffici
suppress
diseas
progress
figur
product
figur
import
suppress
cia
previous
demonstr
mice
cia
refract
treatment
support
notion
relev
cia
mice
treat
also
shown
stimul
product
found
cell
primari
treg
respons
resolv
cia
ectonucleosid
triphosph
hydrolyz
atp
amp
thu
quench
inflammatori
signal
extracellular
atp
also
show
treg
remain
subset
cell
encompass
treg
subset
fact
treg
protect
cia
treg
compos
two
subset
interchang
analysi
induct
treg
vector
reveal
increas
percentag
treg
cia
mice
cia
modest
impact
upon
induct
examin
type
treg
induc
treatment
whole
splenic
drain
ln
lymphocyt
cultur
overnight
cii
puls
pma
ionomycin
ascertain
type
treg
induc
pbsdose
mice
lymphocyt
stain
identifi
treg
subset
sinc
shown
express
treg
queri
whether
treg
may
induc
consequ
treatment
cell
evalu
express
figur
b
upon
examin
splenic
treg
deriv
pbsdose
mice
compar
present
mice
modest
increas
p
frequenc
total
number
cell
observ
figur
g
modest
differ
p
also
observ
frequenc
total
number
splenic
cell
compar
pbsdose
mice
figur
howev
similar
analysi
perform
treg
obtain
drain
ln
increas
frequenc
p
cell
stimul
treatment
compar
present
pbsdose
cia
mice
figur
total
number
ln
treg
also
significantli
p
increas
figur
subsequ
analysi
perform
ln
cell
frequenc
total
number
increas
significantli
p
p
respect
figur
j
studi
demonstr
inde
treg
induc
treatment
cia
mice
addit
analys
perform
cell
figur
examin
splenic
cell
reveal
frequenc
total
number
modestli
significantli
p
reduc
mice
figur
frequenc
splenic
cell
slightli
significantli
p
reduc
figur
total
number
cell
show
differ
pbsdose
cia
mice
figur
similar
analysi
also
perform
ln
cell
treat
cia
mice
slight
reduct
frequenc
ln
cell
observ
mice
figur
total
number
treg
significantli
p
elev
figur
examin
frequenc
ln
cell
also
show
modest
signific
p
reduct
mice
rel
pbsdose
mice
figur
total
number
ln
cell
significantli
p
enhanc
figur
henc
analys
demonstr
treatment
stimul
divers
subset
treg
includ
treg
futur
studi
need
consid
longev
subset
protect
cia
inquir
activ
ln
treg
analysi
product
perform
figur
intracellular
measur
conduct
first
cell
mice
show
cell
p
pbsdose
vectortr
cia
mice
respect
figur
vectortr
mice
show
increas
number
cell
compar
pbsdose
mice
p
figur
examin
cell
reveal
twothird
total
cell
induc
treatment
cia
mice
deriv
subset
figur
cell
induc
result
signific
increas
cell
present
pbsdose
p
vectortr
cia
mice
p
respect
vectortr
mice
show
increas
number
cell
compar
pbsdose
mice
p
figur
find
suggest
inde
treg
predomin
sourc
thu
contribut
amelior
cia
subsequ
treatment
find
may
mimic
evid
human
peripher
blood
treg
treg
found
patient
glomerulonephr
data
present
demonstr
potenc
antiinflammatori
therapeut
moreov
investig
support
multifacet
benefit
adapt
recombin
l
lacti
vector
deliv
therapeut
dose
fact
previou
studi
us
other
use
treat
type
diabet
model
ibd
psoriasi
requir
daili
treatment
recombin
protein
control
diseas
contrast
two
three
oral
dose
suffici
prevent
onset
stop
cia
progress
oral
dose
substanti
advantag
less
invas
circumv
need
inject
llderiv
elimin
laborintens
effort
need
produc
purifi
recombin
protein
dramat
reduc
cost
manufactur
therapeut
moreov
dimer
protein
add
difficulti
cost
gener
l
lacti
use
studi
labadapt
recombin
strain
origin
deriv
industri
dairi
strain
capabl
ferment
milk
product
textur
olfactori
properti
yogurt
previous
demonstr
cur
properti
recombin
l
lacti
maintain
grown
synthet
medium
use
ferment
milk
yogurtlik
product
attribut
make
l
lacti
ideal
tolerogen
deliveri
platform
treatment
autoimmun
diseas
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
